CD19 and cancer: Additionally, a significant phase I/II trial (NCT03056339) carried out at MD Anderson Cancer Center is underway using cord blood-derived CAR-NK cells targeting CD19 in patients with relapsed or refractory CD19+ cancers, such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.